Today's New Buy Pick - Cleveland BioLabs, Inc. (CBLI)

The S&P 500 sank more than 7% just minutes after the open this morning, triggering circuit breakers that temporarily halted trading to prevent a further plunge. Since its all-time high reached on February 19, the S&P 500 is down roughly 18%. The market resumed trading at 9:49am ET, with stocks continuing their decline and the Dow briefly dropping more than 2,000 points as a full-blown oil price war rattled financial markets already on edge over the rapidly spreading coronavirus... Enzo Biochem (NYSE: [ENZ]( Enzo Biochem shares gained as much as 68% on Friday and are up nearly 19% this morning after the company announced that it will begin accepting respiratory specimens this week for its in-house test for the coronavirus. “Clinical laboratories play a vital role .. [Read More]( [My #1 Pick to Double Your Money in 2020]( [This red-hot biotech stock is up a quick double-digits in sheer anticipation of a pending FDA approval announcement.  And it's just getting warmed up... and soon could turn $5,000 into $50,000. We've seen this before, with these stocks skyrocketing 117%... 368%... 626%... 1,100% in mere days. Hurry. It happens fast and you don’t want to miss a penny in profits.]( [Get the details here.]( [You Could Make $300 to $1100 Per Contract With This Simple Trade]( [Imagine getting really good at mastering just ONE simple trade. A trade that appears like clockwork between 9:30-10:45am on most trading days. This free step-by-step guide, by options expert, Dave Acquino, shows you how to spot and take these trades so you can walk away with daily profits! (ad)]( [CLICK HERE for instant access.]( PPC has a big bargain proposition and could be a good defensive buy The market seems set to keep selling off – but is the story really as bad as it seems? The news continues to revolve around coronavirus-induced fear. It’s true that the spread of the virus continues to get bigger; but there are also indications that the worst effects may have already begun tapering off. I noticed a medical report yesterday that concluded not only that the virus had mutated into two different strains, but according to the report, the more deadly of the two – which is the virus that originated in Wuhan, China – also seems to be dropping, while the second, less-deadly strain is the one that is spreading to other parts of the world, including the U.S. [Read More](  [Flip $1,000 into $1.3 Million (without risking a DIME on stocks) -]( [Former Lehman Brothers executive reveals one of Wall Street's best kept secrets. A proven system for turning $1,000 into $1.3 Million (or more) - without touching the stock market.]( [In fact, this system is responsible for the most profitable investment of all time! (ad)]( here for details>>]( Featured Stock [ Cleveland BioLabs, Inc. (CBLI) – Buy Target – $3.75 or better]( Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines.  Other Top Stories [Wall Street circuit breakers trip as markets, crude, plunge]( [Zeppelin wins latest battle of the bands in `Stairway' fight](     [A third Princess cruise ship kept at sea pending virus tests](    [Report: Software pushed jet's nose down 4 times before crash](   Sponsor [First-time "stock flippers" making $30,000+ a month]( [Ever heard of Stock Flipping? Most Americans haven't. It's a growing movement of people who are fed up with the false promises of get-rich-quick real estate investing. And many of them are now making $15,000 to $30,000 a month with less than an hour of work per week. Want to know how they do it?]( [Click here for the free session.](  Trend Following Picks  [(VIPS) – Buy Target – $17.00 or better]( [(BLU) – Buy Target – $10.75 or better]( [(CBB) – Buy Target – $15.00 or better]( [(KIN) – Buy Target – $11.00 or better]( [(AAON) Buy Target – $58.00 or better]( [All Picks]( Reversal Picks  [(TK) Buy Target $3.91 Sell Target $4.57]( [(ARDX) Buy Target $7.25  Sell Target $7.85]( [(GPRO) Buy Target $3.84 Sell Target $4.12]( [(XOMA) Buy Target $24.74 Sell Target $26.31]( [(DHT) Buy Target $6.38 Sell Target $7.31]( [All Picks](  Already subscribed to our premium service? [Click here to Login]( Not a TradersPro subscriber yet? [Learn More About TradersPro Here -  Learn The # 1 Key To Successful Stock Investing Profits](                                --------------------------------------------------------------- This email was sent to {EMAIL} by Investiv, LLC 265 N. Main | Ste. D #283 | Kaysville | UT | 84037 [Forward to a friend]( | [Unsubscribe]( or [Mange which emails you get from TradersPro]( Disclaimers Investing is Inherently Risky There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses. Hypothetical Results Are Reported Results and examples used in the Company’s advertisements, books, videos, websites, and other media—including on the Site and the Network—are, in some cases, based on hypothetical (simulated) trades. Plainly speaking, these trades were not actually executed. Hypothetical performance results have certain limitations. Unlike an actual performance record, hypothetical results do not represent actual trading. Also, since the trades have not been executed, the hypothetical results may have under-or-over compensation for the impact, if any, of certain market factors, such as lack of liquidity. Hypothetical trading programs generally are also subject to the fact that they are designed with the benefit of hindsight. Hypothetical results also do not account for commissions or slippage. The Company’s simulations assume purchase and sale prices believed to be attainable. Yet traders are going to be getting into trades at different times and using various exit approaches, which may result in different pricing and outcomes. You may or may not receive the best available price on the purchase or the sale of a position in actual trading. Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Company’s software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified. Offers Disinterested Commentary and Analysis The Company does not receive any form of payment or other compensation for publishing information, news, research, or any other material concerning specific securities on the Network that is intended to affect or influence the value of securities. The Company, and its personnel, do not engage in front-running of recommendations and do not trade against one’s own recommendations. The Company and its management may benefit from an increase or decrease in the share prices of the profiled companies, and/or may have other actual or potential conflicts of interest. If a particular security featured in a newsletter publication is concurrently owned by the Company in its corporate brokerage account, or in any of the individual accounts of the Company’s principals or analysts / writers, that fact will be disclosed. The Company, its principals, analysts and writers may choose to purchase a security or derivative featured in one of its newsletter publications, but typically will wait three (3) trading days from the date of publication before initiating said purchase. [Disclaimers, Terms & Conditions]( | [Privacy Policy]( Copyright © 2019